ReviewDiagnostics (Basel, Switzerland)2023
Endoscopy in IBD: When and How?
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Purplish Terminal Ileum: Adult IgA Vasculitis Mimicking Crohn's Disease.ACG case reports journal · 2026Article
- Computed tomography enterography-based deep learning radiomics models of intestinal lesions and perienteric fat for predicting Crohn's disease activity: a multicenter cohort study.Quantitative imaging in medicine and surgery · 2026Article
- The CT-based attenuation index of peri-bowel adipose tissue can predict disease progression in inflammatory bowel disease patients.European radiology · 2026Article
- A bibliometric study and visualization analysis of the current status and perspectives in upper tract urothelial carcinoma.Medicine · 2026Article
- Beyond conventional endoscopy: Image-enhanced techniques in quiescent ulcerative colitis assessment.World journal of gastrointestinal endoscopy · 2026Review
- Nrf2 as a Molecular Guardian of Redox Balance and Barrier Integrity in IBD.Antioxidants (Basel, Switzerland) · 2025Review
- Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up.Inflammatory bowel diseases · 2025Article
- Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review.Bioengineering & translational medicine · 2025Review
- Increased CT Attenuation of Pericolic Adipose Tissue as a Noninvasive Marker of Disease Severity in Ulcerative Colitis.Korean journal of radiology · 2025Article
- How Artificial Intelligence Will Transform Clinical Care, Research, and Trials for Inflammatory Bowel Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Review
- Automatic measurement of mesenteric vascular and portal vein parameters via PE-NET in the diagnosis of Crohn's disease.Frontiers in medicine · 2025Article
- Assessment of intestinal luminal stenosis and prediction of endoscopy passage in Crohn's disease patients using MRI.Insights into imaging · 2024Article
- Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases: A Narrative Review.Journal of clinical medicine · 2024Review
- Advancements in the use of AI in the diagnosis and management of inflammatory bowel disease.Frontiers in robotics and AI · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopy is an essential tool supporting inflammatory bowel disease diagnosis, and ileocolonoscopy is essential to the diagnostic process because it allows for histological sampling. A decent description of endoscopic lesions may lead to a correct final diagnosis up to 89% of the time. Moreover, endoscopy is key to evaluating endoscopic severity, which in both Crohn's disease and ulcerative colitis is associated with worse disease outcomes (e.g., more frequent advanced therapy requirements or more frequent hospitalizations and surgeries). Endoscopic severity should be reported according to validated endoscopic scores, such as the Mayo endoscopic subscore (MES) or the ulcerative colitis endoscopic index of severity (UCEIS) for ulcerative colitis, the Rutgeerts score for postoperative Crohn's recurrence, and the Crohn's disease endoscopic index of severity (CDEIS) or the simplified endoscopic score for Crohn's disease (SES-CD) for luminal Crohn's disease activity. The measuring of endoscopic activity has become a regulatory agency requirement to increase the objective evaluation of disease activity and drug response. In recent years, the central reviewing of endoscopic videos has become a standard for clinical trials. However, the adjudication paradigm and the type of endoscopic reading may substantially affect trial outcomes, and the reproducibility of all endoscopic scores is not perfect as they require the interpretation of intrinsically subjective images. This paper reviews and discusses the available evidence on inflammatory bowel disease endoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.